Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.31 |
| ▸ | KAT7 | O95251 | 2/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104916 | 0.85 | CNR1 (0.31) | KAT6AKAT7KAT5KAT8 | |
| SCHEMBL140375 | 0.84 | HPGD (0.34) | KAT6AKAT7KAT5KAT8MALT1 | |
| SCHEMBL140752 | 0.83 | TTK (0.36) | — | |
| SCHEMBL135511 | 0.79 | MALT1 (0.36) | KAT6AKAT7KAT5KAT8SYK | |
| SCHEMBL104406 | 0.72 | TTK (0.33) | — | |
| SCHEMBL104784 | 0.71 | GPR119 (0.33) | KAT6AKAT7KAT5KAT8 | |
| SCHEMBL105076 | 0.70 | TTK (0.34) | KAT7 | |
| SCHEMBL140248 | 0.69 | TTK (0.56) | — | |
| SCHEMBL139126 | 0.67 | TTK (0.41) | — | |
| SCHEMBL10282607 | 0.67 | TTK (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | KAT6A 2397/4885KAT7 593/4885KAT5 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.